Terril Brothers Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 8.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,419 shares of the company’s stock after purchasing an additional 105 shares during the period. Terril Brothers Inc.’s holdings in Johnson & Johnson were worth $220,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently made changes to their positions in the company. Factory Mutual Insurance Co. raised its holdings in shares of Johnson & Johnson by 0.8% in the first quarter. Factory Mutual Insurance Co. now owns 559,300 shares of the company’s stock valued at $86,692,000 after purchasing an additional 4,500 shares during the last quarter. Tempus Wealth Planning LLC increased its position in shares of Johnson & Johnson by 1.3% during the first quarter. Tempus Wealth Planning LLC now owns 15,546 shares of the company’s stock valued at $2,410,000 after acquiring an additional 195 shares during the last quarter. Cooke & Bieler LP increased its position in shares of Johnson & Johnson by 9.6% during the first quarter. Cooke & Bieler LP now owns 908,354 shares of the company’s stock valued at $140,795,000 after acquiring an additional 79,920 shares during the last quarter. Wrapmanager Inc. increased its position in shares of Johnson & Johnson by 1.4% during the first quarter. Wrapmanager Inc. now owns 6,063 shares of the company’s stock valued at $940,000 after acquiring an additional 83 shares during the last quarter. Finally, NewEdge Wealth LLC increased its position in shares of Johnson & Johnson by 7.4% during the first quarter. NewEdge Wealth LLC now owns 113,024 shares of the company’s stock valued at $17,519,000 after acquiring an additional 7,799 shares during the last quarter. Institutional investors own 67.57% of the company’s stock.
Analyst Ratings Changes
A number of analysts recently issued reports on the stock. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Stifel Nicolaus raised their target price on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Morgan Stanley reissued an “equal weight” rating and issued a $187.00 target price on shares of Johnson & Johnson in a research report on Friday, July 21st. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday. They issued a “strong-buy” rating for the company. Finally, Raymond James raised their target price on Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research report on Monday, July 24th. Eight investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $171.80.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $172.40 on Thursday. The business has a 50 day moving average of $165.77 and a 200 day moving average of $161.28. The company has a market capitalization of $448.06 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 2.91 and a beta of 0.54. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. Johnson & Johnson’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.59 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be paid a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.76%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
Insiders Place Their Bets
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. Insiders sold 47,163 shares of company stock valued at $7,928,856 over the last three months. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- 3 Ways to Play the Upcoming NFL Season
- Conference Calls and Individual Investors
- The TJX Companies: Offprice Retail Hits its Stride in Q2
- Most Active Stocks: Dollar Volume vs Share Volume
- Target Misses The Mark: Is It Too Late To Sell?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
